Бельгия - английский - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires sterop sa-nv - magnesium sulfate heptahydrate 100 mg/ml - eq. magnesium 9,87 mg/ml - solution for injection - 1 g/10 ml - magnesium sulfate heptahydrate 100 mg/ml - magnesium sulfate

Израиль - английский - Ministry of Health

inovamed ltd - magnesium sulfate as heptahydrate - solution for injection / concentrate for solution for inj/inf - magnesium sulfate as heptahydrate 500 mg / 1 ml - magnesium sulfate - magnesium sulfate 50%w/v inovamed is indicated for:1. the treatment of magnesium deficiency in hypomagnesaemia. 2. the prevention and treatment of hypomagnesaemia in patients receiving total parenteral nutrition. 3. the control and prevention of seizures in severe pre-eclampsia. 4. the control and prevention of recurrent seizures in eclampsia

Израиль - английский - Ministry of Health

a.l. medi-market ltd. - magnesium sulfate heptahydrate - solution for injection / concentrate for solution for inj/inf - magnesium sulfate heptahydrate 500 mg / 1 ml - magnesium sulfate - magnesium sulfate kalceks 50% solution for injection or infusion is indicated for: the treatment of magnesium deficiency in hypomagnesaemiathe prevention and treatment of hypomagnesaemia in patients receiving total parenteral nutritionthe control and prevention of seizures in severe pre-eclampsiathe control and prevention of recurrent seizures in eclampsia

Ирландия - английский - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - magnesium - granules for oral solution - 5 millimole(s) - magnesium aspartate

Мальта - английский - Medicines Authority

aldox limited school street tarxien, malta - magnesium hydroxide - effervescent powder - magnesium hydroxide 56.25 g - drugs for acid related disorders

Мальта - английский - Medicines Authority

aldox limited school street tarxien, malta - magnesium hydroxide - powder for oral suspension - magnesium hydroxide 63 g - drugs for acid related disorders

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 97mg (4mmol)) chewable tablets (neoceuticals ltd - magnesium glycerophosphate - chewable tablet - 97.2mg

Соединенные Штаты - английский - NLM (National Library of Medicine)

american health packaging - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. in infants 1 month to less than 1 year, esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated gerd. maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with

Соединенные Штаты - английский - NLM (National Library of Medicine)

dr. reddy's laboratories limited - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered.   in infants 1 month to less than 1 year, esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated gerd.   maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months.   symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with ger

Соединенные Штаты - английский - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 40 - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules, usp are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules, usp may be considered. maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules, usp are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules, usp are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults. esomeprazole magnesium delayed-release capsules, usp are indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in p